Cardinal Health Explores Oncologists’ Views on Therapies

Dec 07, 2017
By Pharmaceutical Executive Editors

Cardinal Health Specialty Solutions, healthcare services and products company, released its second edition of Oncology Insights. The research-based report outlines the views of over 200 oncologists in the US pertaining to the latest medical advances and potential for treatments.

The report found that:

  • Fifty-one percent of oncologists see CAR T-cell therapy as a game-changing approach to cancer treatment, but barriers such as cost, toxicity and complex administration could lead to slow uptake.
  • As more biosimilars enter the U.S. market, oncologists are open to prescribing them in place of their reference products; and 66% have high expectations about the cost savings biosimilars will deliver for their practices.
  • With three targeted therapies recently approved for acute myeloid leukemia (AML), most oncologists (85%) are routinely prescribing genetic tests for AML patients – and a growing number (31%) are now referring AML patients to academic medical centers for treatment.

lorem ipsum